A 28-year-old woman from Delhi presents with amenorrhea for 8 months and progressive weight gain of 12 kg over the past 2 years. She reports irregular periods since menarche, excessive facial hair, and acne. On examination: BMI 31 kg/m², hirsutism (Ferriman–Gallwey score 18), acanthosis nigricans on neck and axillae. Pelvic ultrasound shows bilateral ovarian cysts (8–10 mm) with increased stromal echogenicity. Hormonal profile: LH 18 mIU/mL (normal 2–10), FSH 6 mIU/mL (normal 3–12), LH:FSH ratio 3:1, free testosterone 8 pg/mL (normal 0.5–2.5), fasting insulin 22 µIU/mL (normal < 12), fasting glucose 108 mg/dL. What is the most appropriate next step in the management of this patient?

Explanation

## Clinical Diagnosis **Key Point:** This patient has PCOD (polycystic ovarian disease) with clinical and biochemical hyperandrogenism, insulin resistance, and metabolic dysfunction. The diagnosis is established by Rotterdam criteria (irregular cycles + hyperandrogenism + ultrasound findings). ## Pathophysiology of Insulin Resistance in PCOD Insulin resistance is present in 50–70% of PCOD patients and drives: - Increased LH secretion via GnRH hypersensitivity - Androgen excess from theca cells - Anovulation and amenorrhea - Acanthosis nigricans (marker of severe insulin resistance) ## Management Algorithm ```mermaid flowchart TD A[PCOD diagnosed]:::outcome --> B{Insulin resistance present?}:::decision B -->|Yes: Fasting insulin > 12, Acanthosis nigricans| C[Metformin + Lifestyle modification]:::action B -->|No| D[COCP ± antiandrogen]:::action C --> E[Improves insulin sensitivity, reduces androgen, restores ovulation]:::outcome D --> F[Suppresses androgen, regulates cycles]:::outcome C --> G[Reassess in 3 months]:::action ``` ## Why Metformin First in This Patient | Feature | This Patient | Clinical Significance | |---------|--------------|----------------------| | Fasting insulin | 22 µIU/mL (elevated) | Severe insulin resistance | | Acanthosis nigricans | Present | Marker of metabolic syndrome | | BMI | 31 kg/m² | Obese, high cardiometabolic risk | | Fasting glucose | 108 mg/dL (impaired) | Prediabetic range | **High-Yield:** Metformin is first-line in PCOD with insulin resistance because it: 1. Reduces hepatic glucose production 2. Improves peripheral insulin sensitivity 3. Decreases LH and androgen levels 4. Restores ovulation in 20–30% of anovulatory women 5. Reduces risk of type 2 diabetes (31% risk reduction in PCOD cohorts) ## Lifestyle Modification **Clinical Pearl:** A 5–10% weight loss in obese PCOD patients can: - Restore ovulation in 30–50% - Improve insulin sensitivity by 30–40% - Reduce androgen levels - Lower cardiovascular risk This is synergistic with metformin and should be emphasized. ## Timing of COCP Oral contraceptives are added if: - Amenorrhea persists after 3 months of metformin + lifestyle change, OR - Patient desires contraception, OR - Hirsutism/acne requires suppression (add spironolactone 50–100 mg daily) [cite:Revised Rotterdam Criteria 2012; ASRM PCOD Guideline 2018]